United Therapeutics has high revenue growth and low debt. Read why UTHR stock is undervalued with solid financial metrics and ...

United Therapeutics shares have sunk to $308.27, producing a disappointing 14% loss - worse than the S&P 500’s 1.4% drop.

A month has gone by since the last earnings report for United Therapeutics (UTHR). Shares have lost about 4.8% in that time frame, underperforming the S&P 500. Will the recent negative trend continue ...

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital ... we are going to take a look at where United Therapeutics Corporation (NASDAQ:UTHR ...

It's early days for xenotransplantation, but eGenesis, Eledon, United Therapeutics and more are working to develop solutions ...

United Therapeutics, which belongs to the Zacks Medical - Drugs industry, posted revenues of $735.9 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 1.46%.

United Therapeutics Corp. operates as a biotechnology company, which engages in the development and commercialization of unique products to address the unmet medical needs of patients with chronic ...